Buried Dysplasia and Early Adenocarcinoma Arising in... : The American Journal of Surgical Pathology (original) (raw)

Original Articles

Buried Dysplasia and Early Adenocarcinoma Arising in Barrett Esophagus After Porfimer-photodynamic Therapy

Mino-Kenudson, Mari MD*; Ban, Shinichi MD†; Ohana, Masaya MD* ‡; Puricelli, William RN§; Deshpande, Vikram MD*; Shimizu, Michio MD†; Nishioka, Norman S. MD§; Lauwers, Gregory Y. MD* †

*Department of Pathology, Gastrointestinal Pathology Service

§Division of Gastroenterology, Massachusetts General Hospital, Boston, MA

†Department of Pathology, Saitama Medical School, Saitama

‡Department of Gastroenterology, Tenri Hospial, Tenri, Japan

Reprins: Gregory Y. Lauwers, MD, Gastrointestinal Pathology Service, Department of Pathology (WRN No. 2), Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114-2696 (e-mail: [email protected]).

The American Journal of Surgical Pathology 31(3):p 403-409, March 2007. | DOI: 10.1097/01.pas.0000213407.03064.37

Abstract

The restoration of squamous epithelium after photodynamic therapy (PDT) for Barrett esophagus (BE) and its related neoplasms has been noted. It may result in the development of buried neoplasms and/or BE underneath restored squamous epithelium which maintain their potential for malignant transformation. The purpose of this study was to evaluate the prevalence, endoscopic, and histologic characteristics and also response to further treatment of buried neoplastic epithelium developing after PDT. Fifty-two BE patients with high-grade dysplasia (n=19), intramucosal adenocarcinoma (n=28), and invasive adenocarcinoma (n=5) were treated with porfimer PDT. Buried neoplasms completely covered by squamous epithelium were seen in 1 patient before and in 13 patients after PDT. Their prevalence was 0.6% and 7.4% of pre and post-PDT biopsy levels positive for neoplasia (_P_=0.001). Buried neoplasms, representing the highest grade of residual neoplasm, were noted in a series of 11 post-PDT endoscopies (7.1% of 155 post-PDT endoscopies with neoplastic diagnoses) of 8 patients. Their occurrence after PDT was neither associated with the length of BE, the diffuseness of neoplasms nor the presence of buried lesions before treatment. There was no prevalent location for these lesions in relation to the original segment of BE, although the majority of both surface and buried neoplasms were found in the prior neoplastic sites. Patients with buried neoplasms responded to further treatment similarly to those with only surface neoplasms (8 of 13 vs. 17 of 24) (_P_=0.33). In conclusion, buried neoplasms are not uncommon after PDT. Thorough endoscopic surveillance with extensive biopsies, especially of the sites previously positive for neoplasia is important to avoid overlooking buried neoplasms that may progress.